CD22 and diffuse large B-cell lymphoma: Moreover, the Alexander trial administered CD19/CD22 dual-targeted CAR T cells plus pembrolizumab to 8 diffuse large B cell lymphoma (DLBCL) patients, with 75% ORR and 63% CR.